China SXT Pharmaceuticals, Inc. SXTC
What this company does
Written from the business description in China SXT Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 1 July 2026. Every sentence was checked against that document before publication.
Revenue compounded at −24.9% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 27 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Income tax $B | · | · | · | · | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow $B | · | −0.0 | −0.0 | · | · | · | 0.0 | −0.0 | 0.0 | 0.0 |
| EPS, diluted $ | −9.13 | −348.17 | −4285.66 | −177.84 | −137.92 | −3.82 | 1.66 | −0.30 | 0.06 | 0.06 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | −27.5 | −22.5 | −21.7 | −38.6 | −35.8 | −21.7 | −100.3 | 21.4 | 46.2 | 64.0 |
| Shares out B | · | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 10 of 19 fiscal years. 47 checks could not be computed.